Get the Stockscreener App
1.63
1.24%
0.02
After Hours:
1.69
0.06
+3.68%
Quince Therapeutics Inc stock is traded at $1.63, with a volume of 176.34K.
It is up +1.24% in the last 24 hours and down -7.91% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$1.61
Open:
$1.6
24h Volume:
176.34K
Relative Volume:
0.78
Market Cap:
$87.55M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-1.9405
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
-3.55%
1M Performance:
-7.91%
6M Performance:
+16.43%
1Y Performance:
+154.29%
1-Day Range:
$1.584
$1.71
1-Week Range:
$1.584
$1.71
52-Week Range:
$0.61
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.63 | 89.70M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Is Quince Therapeutics Inc. stock poised for growthPortfolio Update Report & Risk Controlled Swing Trade Alerts - Newser
Quince Therapeutics Inc. stock momentum explainedJuly 2025 Closing Moves & Reliable Volume Spike Trade Alerts - Newser
Historical volatility pattern of Quince Therapeutics Inc. visualizedEarnings Summary Report & Daily Stock Momentum Reports - Newser
Quince Therapeutics Inc. stock prediction for this week2025 Trading Volume Trends & Fast Gain Stock Trading Tips - Newser
Analyzing drawdowns of Quince Therapeutics Inc. with statistical toolsLong Setup & Consistent Return Strategy Ideas - Newser
New Product Launches: Will They Boost Quince Therapeutics Inc. Stock in 2025July 2025 Spike Watch & Community Consensus Trade Signals - Newser
Is this a good reentry point in Quince Therapeutics Inc.Market Growth Summary & Free Expert Approved Momentum Trade Ideas - Newser
Quince Therapeutics Inc. stock chart pattern explainedJuly 2025 Action & High Accuracy Swing Entry Alerts - Newser
Momentum divergence signals in Quince Therapeutics Inc. chartMarket Trend Report & Growth-Oriented Investment Plans - Newser
Building trade automation scripts for Quince Therapeutics Inc.July 2025 Sentiment & Fast Gain Swing Trade Alerts - Newser
Real time social sentiment graph for Quince Therapeutics Inc.Market Sentiment Report & AI Forecast for Swing Trade Picks - Newser
Published on: 2025-08-19 14:00:59 - Newser
Is Quince Therapeutics Inc. a candidate for recovery playWeekly Trade Report & AI Enhanced Market Trend Forecasts - Newser
Ranking Quince Therapeutics Inc. among high performing stocks via toolsRate Hike & Scalable Portfolio Growth Ideas - Newser
Trend Reversal Possible in Quince Therapeutics Inc. Charts IndicateQuarterly Performance Summary & Comprehensive Market Scan Insights - 선데이타임즈
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.14 Average Target Price from Brokerages - Defense World
Is it time to cut losses on Quince Therapeutics Inc.July 2025 Review & Technical Pattern Alert System - Newser
Should you hold or exit Quince Therapeutics Inc. nowJuly 2025 EndofMonth & Weekly Setup with High ROI Potential - Newser
What candlestick patterns are forming on Quince Therapeutics Inc.2025 Market Trends & Detailed Earnings Play Strategies - Newser
Quince Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Rallies & Free Safe Capital Growth Stock Tips - beatles.ru
Using data tools to time your Quince Therapeutics Inc. exit2025 Performance Recap & Step-by-Step Swing Trade Plans - Newser
Price Channel Expanding on Quince Therapeutics Inc.’s ChartJuly 2025 Action & Weekly Top Gainers Trade List - newsyoung.net
Exit strategy if you’re trapped in Quince Therapeutics Inc.Forecast Cut & AI Driven Stock Movement Reports - Newser
What Fibonacci levels say about Quince Therapeutics Inc. reboundPortfolio Performance Report & Advanced Swing Trade Entry Alerts - Newser
Analyzing recovery setups for Quince Therapeutics Inc. investors2025 Performance Recap & AI Driven Stock Reports - Newser
Custom strategy builders for tracking Quince Therapeutics Inc.Earnings Overview Summary & Stock Portfolio Risk Management - Newser
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):